600056 中国医药
2025/03 - 三个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)1.3984.5809.3686.982--
总资产报酬率 ROA (%)0.4691.4732.8592.196--
投入资产回报率 ROIC (%)0.7282.3544.7343.594--

边际利润分析
销售毛利率 (%)10.59510.71411.29112.62714.396
营业利润率 (%)3.6872.7284.3073.1912.586
息税前利润/营业总收入 (%)4.1393.3654.5143.5503.206
净利润/营业总收入 (%)2.7502.0113.1992.3631.971

收益指标分析
经营活动净收益/利润总额(%)94.972122.21280.615121.618186.516
价值变动净收益/利润总额(%)2.5326.552-0.9034.4254.417
营业外收支净额/利润总额(%)-0.0122.268-1.937-0.2990.316

偿债能力分析
流动比率 (X)1.5551.5351.5841.495--
速动比率 (X)1.2201.2021.2381.158--
资产负债率 (%)59.82460.00562.87763.312--
带息债务/全部投入资本 (%)37.84137.58235.64538.609--
股东权益/带息债务 (%)138.460137.669143.241129.484--
股东权益/负债合计 (%)56.14455.83649.14747.581--
利息保障倍数 (X)9.1475.86515.6439.6485.241

营运能力分析
应收账款周转天数 (天)147.345140.155125.141116.4460.000
存货周转天数 (天)70.06270.63564.36664.3380.000